Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer···【more】
Release date：2024-08-09Recommended：268
Exkivity reduces the growth of non-small cell lung cancer by binding to and inhi···【more】
Release date：2024-08-09Recommended：237
Exkivity works by binding to and blocking EGFR exon 20 insertion mutations, whic···【more】
Release date：2024-08-09Recommended：268
Exkivity was granted accelerated FDA approval in 2021 based on results from the ···【more】
Release date：2024-08-09Recommended：287
Exkivity capsules can be used by adults with non-small cell lung cancer that has···【more】
Release date：2024-08-09Recommended：203
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date：2024-08-09Recommended：233
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date：2024-08-09Recommended：222
Capmatinib targets the activity of MET receptors and blocks the tumor cell growt···【more】
Release date：2024-08-08Recommended：269
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-comp···【more】
Release date：2024-08-08Recommended：259
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosin···【more】
Release date：2024-08-08Recommended：259
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and bloc···【more】
Release date：2024-08-08Recommended：225
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date：2024-08-08Recommended：252
